Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0~102.0% Factory

Inkcazelo emfutshane:

Igama leKhemikhali: Lenvatinib Mesylate

CAS: 857890-39-2

Uvavanyo: 98.0 ~ 102.0%

Imbonakalo: Imhlophe ukuya kwiPowder eNgaphandle-Mhlophe okanye iiCrystals

Qhagamshelana: UGqr. Alvin Huang

Iselula/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

I-Ruifu Chemical Supply Lenvatinib Mesylate Intermediate with High Purity
Lenvatinib Mesylate CAS 857890-39-2
I-4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
I-Desquinolinyl Lenvatinib;I-1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
I-4-Amino-3-Chlorophenol CAS 17609-80-2
I-4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4

Iipropati zeMichiza:

Igama leMchiza	Lenvatinib Mesylate
Izithethantonye	4- [3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-Methoxy-6-Quinolinecarboxamide Mesylate;E 7080 Mesylate;Lenvima
Inombolo yeCAS	857890-39-2
Inombolo yeCAT	RF-PI1975
Ubume beStokhwe	Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni
Ifomula yeemolekyuli	I-C21H19N4O4Cl.CH4O3S
Ubunzima beMolekyuli	522.96
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Mhlophe ukuya kwiPowder eNgaphandle-Mhlophe okanye iiCrystals
Ukuchongwa	Nge-IR;NgeUV;Nge-HPLC
Ukunyibilika	Inyibilika kancinane emanzini, ayinyibiliki kwi-Ethanol
Indawo yokunyibilika	228.0 ~ 230.0℃
Isiqulatho samanzi (KF)	<1.00%
Intsalela kwi-Ignition	<0.10%
Iintsimbi ezinzima	<20ppm
Izinto ezinxulumeneyo
Nakuphi na Ukungacoceki Okukodwa	<0.50%
Ukungcola ngokupheleleyo	<1.00%
Indlela yoVavanyo / yoHlahlelo	98.0 ~ 102.0% (HPLC Isiseko sokomisa)
Unizi lolwapho kuyiwa khona	0.40gm/ml~0.60gm/ml
Umgangatho woVavanyo	Umgangatho woShishino
Ukusetyenziswa	API

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma

Izinto eziluncedo:

FAQ:

Isicelo:

I-Lenvatinib Mesylate (i-CAS: 857890-39-2) i-inhibitor yomlomo kunye ne-multi-targeted inhibitor ye-VEGFR1-3, FGFR1-4, PDGFR, KIT, kunye ne-RET, kunye nemisebenzi enamandla ye-antitumor.I-Lenvatinib Mesylate yi-receptor tyrosine kinase (RTK) inhibitor ene-selectivity ye-VEGFR2.Ibonisa umsebenzi we-antineoplastic, kwaye ibonakaliswe ukunyangwa kwezigulane ezine-recurrent local or metastatic, progressive, radioactive iodine (RAI) -refractory differentiated cancer cancer.I-Lenvatinib Mesylate yavunywa kuqala yi-US Food and Drug Administration (FDA) ngo-Feb 13, i-2015, emva koko yavunywa yi-Arhente ye-Pharmaceuticals kunye ne-Medical Devices Agency yaseJapan (PMDA) ngo-Mar 26, i-2015, kwaye yamkelwa yi-European Medicine Agency (EMA) ngo. NgoMeyi 28, 2015. Yaphuhliswa kwaye yathengiswa njengeLenvima® nguEisai.I-Lenvatinib Mesylate yi-receptor yomlomo ye-tyrosine kinase inhibitor enendlela ekhethekileyo yokubopha ethintela ngokukhethekileyo imisebenzi ye-kinase ye-vascular endothelial growth factor (VEGF) receptors, ngaphezu kwezinye i-proangiogenic kunye ne-oncogenic pathway-related tyrosine kinases ekucingelwa ukuba ibandakanyeka ekwandeni kwe-tumor. .Iboniswa kunyango lwe-progressive radioiodine-refractory differentiated thyroid cancer.Lenvimaisetyenziswa yona ngokwayo ukunyanga umhlaza wegilo (differated thyroid cancer) (DTC), uhlobo lomhlaza wedlala lengqula ongasakwaziyo ukunyangwa nge-iodine ene-radioactive kwaye iyaqhuba.I-LENVIMA isetyenziswa kunye nelinye iyeza elibizwa ngokuba yi-everolimus ukunyanga abantu abadala abanohlobo lomhlaza wezintso olubizwa ngokuba yi-Advanced renal cell carcinoma (RCC) emva kwekhosi enye yonyango kunye nelinye iyeza lokuchasa umhlaza.